• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Pluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Submission of Matters to a Vote of Security Holders

    7/3/25 1:30:30 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email
    false 0001158780 0001158780 2025-06-30 2025-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K 

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): July 3, 2025 (June 30, 2025)

     

    PLURI INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Nevada   001-31392   98-0351734
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    MATAM Advanced Technology Park     
    Building No. 5    
    Haifa, Israel   3508409
    (Address of Principal Executive Offices)   (Zip Code)

     

    011 972 74 710 8600

    (Registrant’s telephone number, including area code)

     

    Not applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Shares, par value $0.00001 per share   PLUR   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

     

    On June 30, 2025, Pluri Inc. (the “Company”), held its 2025 Annual Meeting of Shareholders (the “2025 Annual Meeting”). As a result of the voting outcome at the 2025 Annual Meeting, Mr. Doron Birger was not re-elected to the Company’s Board of Directors (the “Board”) and therefore ceased to serve as a director and as a member of the respective committees on which he serves, effective immediately. Prior to his departure, Mr. Birger was an independent director, Chairman of the Audit Committee, and the sole member of the Investment Committee.

     

    On June 30, 2025, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) that due to Mr. Birger’s departure, the Company is no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Audit Committee to be comprised of at least three independent directors. On July 2, 2025, the Company received a letter from the Listing Qualifications Department of Nasdaq, notifying the Company that consistent with Listing Rule 5605(c)(4), Nasdaq will provide the Company a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A), which will expire on the earlier of (i) the Company’s next annual meeting of shareholders or June 30, 2026, or (ii) if the Company’s next annual meeting of shareholders is held before December 29, 2025, then the Company must evidence compliance no later than June 30, 2026. The Company intends to appoint an additional independent director to the Board and the Audit Committee prior to the expiration of the applicable cure period.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On June 30, 2025, the Company held its 2025 Annual Meeting. The results of shareholders voting at the 2025 Annual Meeting are set forth below:

     

    Proposal No. 1 - Election of Directors

     

    The shareholders cast the following votes for the following individuals nominated as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

     

    Director Name  For   Against   Abstain   Broker
    Non-Votes
     
    Zami Aberman   3,655,962    37,872    297,831    778,972 
                         
    Doron Birger   1,270,717    2,720,350    598    778,972 
                         
    Rami Levi   3,977,009    13,754    901    778,972 
                         
    Maital Shemesh-Rasmussen   3,974,994    15,840    831    778,972 
                         
    Yaky Yanay   3,930,082    60,997    598    778,972 
                         
    Alexandre Weinstein   3,942,043    49,033    601    778,972 

     

    1

     

     

    Proposal No. 2 - Ratification of the selection of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2025.

     

    For   Against   Abstain   Broker
    Non-Votes
    5,164,886   16,289   8,735   N/A

     

    Proposal No. 3 – To Consider and approve the Company’s 2016 Equity Compensation Plan.

     

    For   Against   Abstain   Broker
    Non-Votes
    3,914,964   69,257   7,443   778,972

     

    Proposal No. 4 – To consider and approve, by a nonbinding advisory vote, the compensation of the Company’s named executive officers as described in the accompanying proxy statement.

     

    For   Against   Abstain   Broker
    Non-Votes
    3,919,160   66,894   5,615   778,972

     

    Proposal No. 5 – To recommend, by a nonbinding advisory vote, the frequency (every one, two or three years) of future advisory votes of shareholders on the compensation of our named executive officers.

     

    1 Year   2 Years   3 Years   Abstain   Broker
    Non-Votes
    1,275,471   2,403,566   8,025   304,630   778,972

     

    In accordance with the shareholder voting results, in which every “Two Years” received the highest number of votes cast on the frequency proposal, and the Company’s Board of Directors’ recommendation in the proxy statement for the 2025 Annual Meeting, the Company’s Board of Directors has determined that future shareholder advisory (non-binding) votes on the compensation of the Company’s named executive officers will occur every two years. Accordingly, the next shareholder advisory (non-binding) vote on executive compensation will be held at the Company’s 2027 annual meeting of shareholders.

     

    Proposal No. 6 – To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercise of common warrants and pre-funded warrants to purchase up to 1,086,768 common shares, which were issued pursuant to a Securities Purchase Agreement dated January 23, 2025, as amended by an Amendment to the Securities Purchase Agreement dated April 25, 2025 between the Company and a company wholly beneficially owned by Mr. Alexandre Weinstein, relating to a private placement offering.

     

    For   Against   Abstain   Broker
    Non-Votes
    3,530,251   47,936   5,668   778,972

     

    The vote total set forth above with respect to Proposal No. 6 excludes shares beneficially owned by Mr. Alexandre Weinstein, which were not counted for purposes of such proposal, as the securities underlying the exercise of warrants and pre-funded warrants are to be issued pursuant to a private placement between the Company and an entity wholly beneficially owned by Mr. Alexandre Weinstein.

     

    The results reported above are final voting results.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PLURI INC.
       
    Date: July 3, 2025 By: /s/ Liat Zalts
      Name:   Liat Zalts
      Title: Chief Financial Officer

     

    3

    Get the next $PLUR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

      NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. This partnership supports

      5/27/25 7:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

      Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer an

      5/15/25 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DarioHealth Announces CFO Transition

      NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity. "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished,

      4/21/25 8:30:00 AM ET
      $BNRG
      $DRIO
      $PLUR
      Building Products
      Industrials
      Medical/Dental Instruments
      Health Care

    $PLUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      7/1/25 4:00:11 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    SEC Filings

    See more
    • Pluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Pluri Inc. (0001158780) (Filer)

      7/3/25 1:30:30 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Pluri Inc.

      DEF 14A - Pluri Inc. (0001158780) (Filer)

      5/27/25 4:00:57 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Inc. filed SEC Form 8-K: Other Events

      8-K - Pluri Inc. (0001158780) (Filer)

      5/27/25 8:30:13 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      7/1/25 4:00:11 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Shemesh-Rasmussen Maital was granted 11,173 shares, increasing direct ownership by 154% to 18,445 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:19 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Levi Rami Avraham was granted 11,173 shares, increasing direct ownership by 156% to 18,314 units (SEC Form 4)

      4 - Pluri Inc. (0001158780) (Issuer)

      2/27/25 4:00:22 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

      HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

      3/6/24 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

      HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

      7/13/23 2:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

      Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

      11/11/24 6:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/13/24 4:34:49 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      2/1/24 4:02:29 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

      SC 13G/A - Pluri Inc. (0001158780) (Subject)

      9/15/23 4:00:03 PM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care